Altered glycolysis results in drug‑resistant in clinical tumor therapy (Review) DOI Open Access
Jinghui Peng, Yangyang Cui, Shipeng Xu

et al.

Oncology Letters, Journal Year: 2021, Volume and Issue: 21(5)

Published: March 11, 2021

Cancer cells undergo metabolic reprogramming, including increased glucose metabolism, fatty acid synthesis and glutamine rates. These enhancements to three major pathways are closely associated with glycolysis, which is considered the central component of cancer cell metabolism. Increasing evidence suggests that dysfunctional glycolysis commonly drug resistance in treatment, aberrant plays a significant role drug‑resistant cells. Studies on development drugs targeting these abnormalities have led improvements efficacy tumor treatment. The present review discusses changes targets cause cells, hexokinase, pyruvate kinase, dehydrogenase complex, transporters, lactate, as well underlying molecular mechanisms corresponding novel therapeutic strategies. In addition, association between oxidative phosphorylation introduced, caused by plasticity. Given has been identified common feature may be strategy develop new benefit patients drug‑resistance.

Language: Английский

State-of-the-Art Liver Cancer Organoids: Modeling Cancer Stem Cell Heterogeneity for Personalized Treatment DOI Creative Commons
Julien Giron‐Michel, Maël Padelli, Estelle Oberlin

et al.

BioDrugs, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

Liver cancer poses a global health challenge with limited therapeutic options. Notably, the success of current therapies in patients primary liver cancers (PLCs) may be attributed to high heterogeneity both hepatocellular carcinoma (HCCs) and intrahepatic cholangiocarcinoma (iCCAs). This evolves over time as tumor-initiating stem cells, or cells (CSCs), undergo (epi)genetic alterations encounter microenvironmental changes within tumor microenvironment. These modifications enable CSCs exhibit plasticity, differentiating into various resistant cell types. Addressing this requires urgent efforts develop personalized treatments guided by biomarkers, specific focus on targeting CSCs. The lack effective precision for PLCs is partly due scarcity ex vivo preclinical models that accurately capture complexity CSC-related tumors can predict responses. Fortunately, recent advancements establishment patient-derived lines organoids have opened new avenues medicine research. organoid (PDO) cultures demonstrated self-assembly self-renewal capabilities, retaining essential characteristics their respective tissues, including inter- intratumoral heterogeneities. emergence PDOs derived from serves patient avatars, enabling investigations stratification, screening anticancer drugs, efficacy testing, thereby advancing field medicine. review offers comprehensive summary constructing PLC-derived PDO models. Emphasis placed role CSCs, which not only contribute significantly but also faithfully ensuing development therapy resistance. exploration PDOs' benefits research undertaken, discussion limitations, particularly terms culture conditions, reproducibility, scalability.

Language: Английский

Citations

1
Interactions between the metabolic reprogramming of liver cancer and tumor microenvironment DOI Creative Commons

Haoqiang Yang,

Jinghui Li, Yuanjie Niu

et al.

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 14, 2025

Metabolic reprogramming is one of the major biological features malignant tumors, playing a crucial role in initiation and progression cancer. The tumor microenvironment consists various non-cancer cells, such as hepatic stellate cancer-associated fibroblasts (CAFs), immune well extracellular matrix soluble substances. In liver cancer, metabolic not only affects its own growth survival but also interacts with other cells by influencing expression release metabolites cytokines (such lactate, PGE2, arginine). This interaction leads to acidification restricts uptake nutrients resulting competition symbiosis. At same time, neighboring during proliferation differentiation processes impacts immunity. article provides comprehensive overview crosstalk between cancer their microenvironment, deepening our understanding relevant findings pathways. contributes further regulation development evasion mechanisms while providing assistance advancing personalized therapies targeting pathways for anti-cancer treatment.

Language: Английский

Citations

1
Protein kinase function of pyruvate kinase M2 and cancer DOI Creative Commons
Xun Chen,

Shangwu Chen,

Dongsheng Yu

et al.

Cancer Cell International, Journal Year: 2020, Volume and Issue: 20(1)

Published: Oct. 29, 2020

Abstract Pyruvate kinase is a terminal enzyme in the glycolytic pathway, where it catalyzes conversion of phosphoenolpyruvate to pyruvate and production ATP via substrate level phosphorylation. PKM2 one four isoforms widely expressed many types tumors associated with tumorigenesis. In addition activity involving metabolic increasing evidence demonstrates that exerts non-metabolic function cancers. has been shown be translocated into nucleus, serves as protein phosphorylate various targets contribute multiple physiopathological processes. We discuss nuclear localization PKM2, its association cancers, regulation activity.

Language: Английский

Citations

63
Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment DOI Creative Commons

Xiuxiu Yang,

Yaxin Guo, Chen Chen

et al.

Immunology, Journal Year: 2021, Volume and Issue: 164(3), P. 476 - 493

Published: July 29, 2021

Abstract In recent years, an increasing number of studies have reported that intestinal microbiota important effect on tumour immunity by affecting the microenvironment (TME). The are closely associated with various immune cells, such as T lymphocytes, natural killer cells (NK cells) and macrophages. Some bacteria, Akkermansia muciniphila (A . muciniphila) Lactobacillus reuteri (L reuteri) , been shown to improve immunity. Furthermore, microbial imbalance, increased abundance Fusobacterium nucleatum (F nucleatum) Helicobacter hepaticus (H hepaticus) generally causes formation progression. addition, some also play roles in immunotherapy, especially PD‐L1‐related therapies. Therefore, what is relationship between these processes how do they affect each other? this review, we summarize interactions corresponding mechanisms among microbiota, system TME facilitate research development new targeted drugs provide approaches therapy.

Language: Английский

Citations

52
Altered glycolysis results in drug‑resistant in clinical tumor therapy (Review) DOI Open Access
Jinghui Peng, Yangyang Cui, Shipeng Xu

et al.

Oncology Letters, Journal Year: 2021, Volume and Issue: 21(5)

Published: March 11, 2021

Cancer cells undergo metabolic reprogramming, including increased glucose metabolism, fatty acid synthesis and glutamine rates. These enhancements to three major pathways are closely associated with glycolysis, which is considered the central component of cancer cell metabolism. Increasing evidence suggests that dysfunctional glycolysis commonly drug resistance in treatment, aberrant plays a significant role drug‑resistant cells. Studies on development drugs targeting these abnormalities have led improvements efficacy tumor treatment. The present review discusses changes targets cause cells, hexokinase, pyruvate kinase, dehydrogenase complex, transporters, lactate, as well underlying molecular mechanisms corresponding novel therapeutic strategies. In addition, association between oxidative phosphorylation introduced, caused by plasticity. Given has been identified common feature may be strategy develop new benefit patients drug‑resistance.

Language: Английский

Citations

46